NOX 0.00% 10.0¢ noxopharm limited

Serindipity, page-3

  1. 4,947 Posts.
    lightbulb Created with Sketch. 790
    Hey Apples thanks for the word of encouragement in the other post

    And while I am here why has Isabell Vocks been replaced by Marinella Messina (dec 5th) with the DARRT study and the primary completion date moved from oct 2018 to Dec 2019 a year delay for what was supposed to be according to RBX posts a fairly fast process.
    https://clinicaltrials.gov/ct2/history/NCT03307629?A=6&B=7&C=Side-by-Side#StudyPageTop

    So to be clear here we first had Ian Minns heading this study, relaced by Isabell Vocks with a change in the study design according to RBX because they were having trouble finding patients with that past design and now Isabell is replaced by Marinella Messina just after two months in the job and the study blown out another 12 months....ummmmmm.

    There would not be a problem with the study would there?
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
0.000(0.00%)
Mkt cap ! $29.22M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
5 52445 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 46575 3
View Market Depth
Last trade - 11.05am 27/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.